“Adalimumab for Nail Psoriasis: Efficacy and Safety from the Open-Label Extension of a Phase-3, Randomized, Placebo-Controlled Trial”. 2017. SKIN The Journal of Cutaneous Medicine 1 (3.1): s97. https://doi.org/10.25251/skin.1.supp.96.